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significant differences either in safety or in efficacy. The third 
controlled trial investigated the clinical efficacy of PHMB 
compared to placebo in the treatment of human papilloma 
virus. Patients treated with PHMB daily for up to 16-weeks 
showed significantly higher (52%) clearance of genital warts 
as compared to patients treated with placebo (4%).  Conclu-
sion: PHMB may be a clinically effective alternative for the 
treatment of BV and human papilloma virus. Although 
PHMB-based antiseptics are available since the late 90s, con-
trolled trials to investigate its clinical potential for antiseptic 
treatment are scant. Clinical use of antiseptics for the treat-
ment of infectious diseases should be explored and support-
ed further.  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 The genital tract is an ecosystem for a multiplicity of 
microorganisms which have to be maintained in a fragile 
balance. If this balance is disturbed, infection may occur. 
Infectious diseases of the genital tract caused by bacteria, 
fungi, parasites, and viruses are a worldwide issue and are 
highly evidenced to impair somatic functions including 
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 Abstract 
 Background: In clinical practice, treatment of genital tract 
infections is based on administration of either antibiotics or 
antiseptics. While antibiotics may be applied systemically or 
topically, antiseptics may be applied only topically. In case of 
bacterial vaginosis (BV), antibiotic therapy may often be lim-
ited and side effects due to systemic administration may de-
velop. Polihexanide (PHMB) is a promising option for the top-
ical treatment of genital tract infections, in particular BV and 
vaginitis.  Method: A systematic search for publications on 
the use of PHMB for the treatment of genital infections in 
two electronic databases was performed. Titles, abstracts 
and citations were imported into a reference database. Du-
plicates were removed and two reviewers assessed each 
identified publication separately.  Results: Among a total of 
204 references, 3 prospective randomized trials were identi-
fied. Two trials treated BV infections with PHMB in compari-
son to clindamycin as antibiotic standard therapy with no 
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reproduction  [1, 2] . Additionally, the vaginal flora may be 
a source for surgical site infections  [3] , urogenital tract 
infections during pregnancy  [4] , and newborn infections 
including an increased risk of preterm birth  [5, 6] .
 Mycoplasma hominis is known to decrease fertility in 
males  [7] , whereas  Mycoplasma genitalium and  Chlamy-
dia trachomatis are responsible for infertility in males 
and females  [8, 9] . Equally important are gonococcal in-
fections which can cause urethritis, proctitis, cervicitis, 
and pelvic inflammatory disease with long-term effects 
such as infertility, ectopic pregnancy, and chronic pelvic 
pain  [10] . Enterobacteriaceae like  Escherichia coli or  En-
terococcus faecalis are the most common causes of non-
sexually transmitted infections  [2] .  Pseudomonas aerugi-
nosa as well as Gram-positive cocci that commonly
colonize the male urethra can cause prostatitis and
epididymitis and consecutively impair fertility  [11] .  Can-
dida albicans was associated with male infertility because 
of an inhibitory effect on human sperms  [12] . In the fe-
male genital tract,  C. albicans is a common commensal 
but may also cause vaginitis and cervicitis  [2] . Toxin-pro-
ducing  Staphylococcus aureus strains have been identi-
fied as underlying pathogens for the development of vag-
inal menstrual toxic shock syndrome  [13–15] . Viral geni-
tal tract infections are mostly caused by herpes viruses, 
human papilloma viruses (HPV), and human immuno-
deficiency viruses (HIV) either due to the virus itself or 
to side effects.
 Bacterial vaginosis (BV) is the most common disorder 
of the vaginal flora, caused by different microbial species, 
with a prevalence of 5–30% in adult females  [16–18] . BV 
is associated with an increased risk of acute upper genital 
tract infection  [19, 20] . Vaginitis is the most common gy-
necologic diagnosis secondary to BV  [21] , vulvovaginal 
candidiasis  [22] , or trichomoniasis  [23] .
 Infectious genital tract diseases are commonly treated 
with antibiotics such as clindamycin or metronidazole 
 [24] . Today, antimicrobial chemotherapy is increasingly 
complicated by progressive antibiotic resistance  [25] . 
Moreover, new insights into the structure and function of 
the colonization of the vagina help to explain why antibi-
otic treatment is only of limited use in infections involv-
ing microbial biofilms. The treatment of genital tract in-
fections, in particular vaginosis and vaginitis, is therefore 
still a great challenge. Compared to oral antibiotic thera-
py, local treatment of genital tract infections shows less 
systemically side effects like nausea, vomiting, and taste 
perversion  [26, 27] .
 Modern antiseptics are an excellent alternative to an-
tibiotic treatment, provided that they combine a broad 
antimicrobial spectrum with low toxicity, high tissue 
compatibility, low or missing adsorption, and good ap-
plicability. Therefore, antiseptics are the first option for 
the treatment of local microbial infections.
 In the past, chlorhexidine digluconate (CHX) was 
used as a general vaginal antiseptic for over three decades 
 [28] . However, hyperkeratosis, ulceration, dysplasia, and 
a significant increase in DNA damages by CHX were ob-
served in rat experiments  [29, 30] . Additionally, concen-
tration-dependent CHX significantly inhibits wound 
healing and granulation  [31, 32] , which corresponds with 
the cytotoxic effect on osteoblasts and odontoblast-like 
cells  [33, 34] . Moreover, degradation during storage may 
release the carcinogen 2-chloroanline from low-grade 
CHX  [35] .
 Therefore, other antiseptics like PHMB  [36] and oc-
tenidine  [37] have moved into the focus of antiseptic 
treatment. While PHMB is a structural sibling of CHX, 
it lacks many of its drawbacks because of the lack of 
2-chloroanaline in the molecular structure of PHMB.
 Polihexanide is well tolerated when used topically on 
skin, wounds  [38] , eyes  [39, 40] , and vaginal mucous 
membrane  [41] . Only a negligible allergic risk, very low 
toxicity, and no adsorption of PHMB have been described 
 [36] . Its tissue compatibility and biocompatibility is much 
better than that of CHX in vitro. Because of the addition-
ally higher antimicrobial efficacy, PHMB achieved a bet-
ter biocompatibility index than chlorhexidine and should 
be preferred  [42] . Additionally, PHMB significantly stim-
ulates wound healing  [43] and there is no indication of 
any mutagenicity or carcinogenicity of PHMB in vitro or 
in vivo  [38] .
 The efficacy of PHMB against infected wounds, pros-
theses, carcinomas, and methicillin-resistant  S. aureus 
(MRSA) in vivo has been extensively studied in different 
controlled clinical studies. The antimicrobial activity of 
PHMB based on its exclusive interaction with acidic, neg-
atively charged phospholipids in the bacterial membrane 
leads to increased fluidity, permeability, and loss of integ-
rity, followed by the death of the organism  [44–47] . Trans-
ferred to the cytoplasm it leads to disruption of the bacte-
rial metabolism. Because neutral phospholipids are only 
slightly affected, PHMB has a low toxicity against human 
cells  [38, 48, 49] . PHMB binds to cellular surfaces which 
is why it also has a sustained effect over hours  [39, 50] .
 PHMB is commercially available in many formula-
tions and for different indications including wound anti-
sepsis, rinsing, and decolonization of unwanted organ-
isms (e.g. MRSA) to name only a few. For genital treat-
ment, PHMB is patented as a single-dose, isotonic topical 
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solution (Monogin  ; Lo.Li. Pharma S.r.l., Rome, Italy). 
The purpose of this work is to review the existing litera-
ture on the antiseptic polihexanide (polyhexamethylene 
biguanide; PHMB) for the treatment of genital tract in-
fections.
 Methods 
 A systematic search for manuscripts published in any lan-
guage in the two electronic databases Pubmed and ISI Web of Sci-
ence was performed. The following syntax for literature searches 
in both databases was used:
 – Genital tract infection and PHMB or polihexanide or poly-
hexamethylene biguanide 
 – Vaginosis and PHMB or polihexanide or polyhexamethylene 
biguanide 
 – Vaginitis and PHMB or polihexanide or polyhexamethylene 
biguanide 
 No other limits were used. Bibliographies of manuscripts were 
screened for additional sources and an additional manual search 
was done.
 Studies were included on the basis of four criteria: disease, 
therapy, study design, and outcome. The diseases of interest were 
genital tract infections, especially vaginosis and vaginitis. The 
therapy of interest was treatment with PHMB. Primarily, in vivo 
studies and clinical studies were selected. Additionally, in vitro 
studies were considered to emphasize the efficacy against the dis-
ease-causing pathogen. The outcome of interest was the compar-
ison of PHMB treatment with a placebo or standard therapy.
 All relevant titles, abstracts, and citations were imported into 
a reference database. Duplicates were removed and two reviewers 
independently assessed each publication separately. Differences 
in opinion were discussed among all authors and the final deci-
sion was made by means of open consensus. Both reviewers inde-
pendently abstracted data from all selected studies.
 Results 
 The search results are shown in a flow diagram ( fig. 1 ). 
A total of 204 references were identified from the search-
es of the electronic databases. After omitting 138 dupli-
cate references, 66 original references were further ana-
lyzed. Overall, 21 potentially eligible studies were identi-
fied. The search resulted in one further study. Nineteen 
references were excluded after review of the full text. The 
3 eligible studies identified
138 duplicate records removed
21 potentially eligible studies
identified
19 failed to meet the inclusion
criteria
1 record identified through
a manual search
45 excluded using the published
abstracts and titles because of the
type of intervention and/or 
nonrelevance
66 records identified for initial
screening of titles and abstracts
204 records identified from
electronic database searches
 Fig. 1. Flow diagram outlining the litera-
ture search and review of the studies. 
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three remaining references were prospective randomized 
trials. In two trials, BV infections were treated with 
PHMB in comparison to clindamycin as standard thera-
py. The third trial investigated HPV patients treated with 
PHMB or a placebo in a randomized controlled study ( ta-
ble 1 ).
 In vitro Studies 
 The broad antimicrobial efficacy of PHMB against 
microorganisms frequently causing genital tract infec-
tions has been repeatedly shown in vitro. PHMB was ef-
fective against planktonic  E. coli and  S. aureus as well as 
 P. aeruginosa in suspension and biofilms  [37–42, 51–53] . 
In addition, PHMB was also effective against  E. faecalis 
and  C. albicans  [54] , as well as against intracellular bac-
teria such as  Chlamydia sp. and  Neisseria sp.  [52] , and 
protozoa such as  Acanthamoeba  [53] .
 The virocidal in vitro efficacy of PHMB was investi-
gated in two references. It was shown that 0.01% PHMB 
is effective against herpes viruses in vitro  [58] . Krebs et 
al.  [59] found a modest antiviral efficacy against cell-free 
and cell-associated HIV-1. Furthermore, they found that 
PHMB inhibited binding and entry of the virus.
 Clinical Studies 
 Minozzi et al.  [57] compared the efficacy of a single-
dose PHMB solution (Monogin) versus a 7-day clindamy-
cin cream treatment against BV in a multi-center, ran-
domized, single-blind and parallel-group study which en-
rolled 740 patients. Twenty-one to 30 days after the start 
of the study, the authors found no significant (95% CI,
p = 0.386) differences between both therapy regimes 
 either in safety or in efficacy. Safety was investigated by 
monitoring treatment-emergent adverse events (e.g. uri-
nary tract infection) throughout the study. Namely, 30.4% 
of all PHMB-treated patients and 26.8% of clindamycin-
treated patients had an adverse event, with no statistically 
significant difference. The efficacy was analyzed in a per-
protocol group with 347 patients. Cure of BV in the per-
protocol group was evaluated by frequencies of ‘investiga-
tor cure’ (requirement for additional therapy: 89.1% of the 
PHMB group, 86.4% of the clindamycin group achieved 
cure), ‘clinical cure’ (conservative symptomatic measure: 
64.3% of the PHMB group, 63.2% of the clindamycin 
group achieved cure), ‘Nugent cure’ (diagnostic evalua-
tion: 56.5% of the PHMB group, 57.7% of the clindamycin 
group achieved cure), and ‘therapeutic cure’ (symptom-
atic, interpretive, and diagnostic measures: 42.1% of the 
PHMB group, 45.6% of the clindamycin group achieved 
cure). Pertaining to the results, it seems that a single dose 
of PHMB is statistically equivalently effective to 7 daily 
doses of clindamycin for the treatment of BV.
 Gerli and di Renzo  [41] investigated patients treated 
with the same regimen (PHMB, n = 59; clindamycin, n = 
51) and concluded that mono-dose PHMB treatment 
should be the therapy of choice for BV.
 Marelli et al.  [63] showed in a prospective, double-
blind, randomized placebo trial that PHMB is effective 
Table 1.  Eligible studies
Study
(country)
Type Setting Outcome
Gerli [41] 
(Italy)
Prospective, randomized,
parallel-group study
Among 110 BV patients, the efficacy of a single-dose 
PHMB vaginal gel versus a 7-day clindamycin cream 
treatment against BV was compared
The efficacy of mono-dose 
PHMB treatment was similar to 
7-days clindamycin cream 
treatment
Marelli
et al. [63] 
(Italy)
Prospective,
double-blind, randomized,
placebo trial
HPV patients (n = 140), who applied PHMB daily for up 
to 16 weeks, were cleared of warts in 52% of cases (warts 
clearance in the placebo group, 4%). In a 12-week 
treatment-free follow-up period, wart recurrence was 
investigated. The recurrence rate after a 12-week 
treatment-free follow-up period was 19% in the PHMB 
group and 0% in the placebo group
PHMB is effective for the 
treatment of genital papilloma 
virus infections
Minozzi
et al. [57] 
(Italy)
Prospective, multicenter, 
randomized, single-blind 
and parallel-group study
Among 740 BV patients, the efficacy of a single-dose 
PHMB solution (Monogin) versus a 7-day clindamycin 
cream treatment against BV was compared
There were no significant 
differences between the two 
therapy regimes either in safety 
or in efficacy
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for the treatment of genital papilloma virus infections. 
Patients who applied PHMB daily for up to 16 weeks were 
significantly (p  ! 0.0001) more frequently cleared of 
warts (52%) as compared to patients in the placebo group 
(4%). In a 12-week treatment-free follow-up period, wart 
recurrence was investigated. The recurrence rate after the 
12-week treatment-free follow-up period was 19% in the 
PHMB group and 0% in the placebo group.
 Discussion 
 Genital tract infections are a serious challenge in gy-
necology as well as in urology. In the last decade it has 
become increasingly clear that antimicrobial chemother-
apy is limited by an increasingly prevalent antibiotic re-
sistance. Additionally, frequent and inappropriate use of 
antibiotics promotes resistance even further. With the 
availability of new antiseptic compounds with a broad 
antimicrobial spectrum, provided in easy-to-use and 
well-tolerated formulations, local treatment is expected 
to become more and more important in genital tract ther-
apy of localized limited infections.
 PHMB is a modern antiseptic that combines a broad 
antimicrobial spectrum with low toxicity and without 
long-term risks, and with high tissue compatibility, no 
reported adsorption, and good applicability as solution, 
gel, ointment, or foam  [37] . The modes of action make the 
development of resistance to PHMB highly unlikely. Ac-
tually, no bacterial resistance has been described in vitro 
or from clinical or environmental samples  [69] . The an-
timicrobial efficacy of PHMB is not impaired by protein 
and blood  [71] . The most interesting feature of PHMB is 
its outstanding relation between antimicrobial efficacy 
and low cytotoxicity and exceptional tissue compatibility 
that has been repeatedly described by independent re-
searchers in vitro, in animal models, and in controlled 
clinical studies and case reports. At low concentrations, 
PHMB even seems not only to be nontoxic but also to 
have a positive effect on the proliferation of human kera-
tinocytes that promotes wound healing  [60–62] . It is ac-
tually one of the most promising antiseptic substances 
and has been used in medicine for many indications for 
over 20 years.
 Although the efficacy of PHMB against typical genital 
tract pathogens has been repeatedly demonstrated, the 
number of actual clinical studies published on the topic 
is limited because the introduction of PHMB in clinical 
practice (except in wound antisepsis) only started in the 
last decade. Identified studies show the clinical effective-
ness of PHMB and go along well with results from in vivo 
studies and clinical data from other indications, e.g. 
wound infections and treatment of acanthamoeba kera-
titis  [36] . Minozzi et al.  [57] and Gerli et al.  [41] compared 
the efficacy of a single-dose PHMB solution (Monogin) 
versus 7-day clindamycin cream treatment against BV 
and found no significant differences between the two 
therapy regimes in either safety or efficacy. The mecha-
nism of action of clindamycin is based on the inhibition 
of protein synthesis by binding to the 50S subunit of the 
bacterial ribosome, resulting in a mostly bacteriostatic 
effect. Therefore, the efficacy depends mainly on the pe-
riod of time during which the effective concentration is 
above the minimum inhibitory concentration of the 
pathogen. Because both agents were self-administered by 
the patients, the efficacy depends also on the compliance, 
which is commonly better in cases of single treatment 
with PHMB. 
 Even the antiviral efficacy against genital papilloma-
virus could be demonstrated in a clinical trial  [63] . In the 
past, CHX or antibiotics were often used for the treat-
ment of genital tract infections. The evidence available 
today, though limited, indicates that even a single dose of 
PHMB is comparable to a 7-day antibiotic course but has 
no unwanted effects like induction of antimicrobial resis-
tance.
 Until now, a final evaluation of PHMB in comparison 
to other genital tract antiseptics, e.g. CHX, has not been 
possible because no studies comparing both substances 
are available. Due to the better tissue compatibility of 
PHMB compared with CHX, the in vitro effectiveness of 
PHMB in the presence of a bio-burden, the primary de-
creased susceptibility of enterococci strains against CHX 
 [64] , and the R-plasmid-coded CHX resistance in vitro 
 [65–67] with possible cross-resistance against antibiotics 
 [68] , such studies would be highly appreciated as final 
evidence for the superiority of treatment of genital tract 
infections by PHMB as previously shown for other indi-
cations.
 Conclusion 
 PHMB may be a clinically effective alternative for the 
treatment of BV and HPV. Although PHMB-based anti-
septics have been available since the late 90s, controlled 
trials to investigate its clinical potential for antiseptic 
treatment are scant. Clinical use of antiseptics for the 
treatment of infectious diseases should be explored and 
supported further.
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